Keith McCullagh PhD – KEEP for reference
Keith McCullagh is an experienced bioscience entrepreneur and is also chairman of Xention, Ario Pharma and Torpedo Factory Group. He was previously chairman of Affitech, Pharmacy 2U and Clavis Pharma and from 2004 to 2008 was Chief Executive of Santaris Pharma, an RNA medicines company sold to Roche in 2014.
From 1986 to 1998, Keith was Chief Executive of British Biotech, now Vernalis, a company he founded and built into one of Europe’s first public biopharmaceutical businesses. Prior to British Biotech, he was UK Research Director for GD Searle & Co, Inc., now part of Pfizer.
He holds a degree in Veterinary Medicine from the University of Bristol and a PhD in Pathology from the University of Cambridge.
- Annual Report and Accounts
- Kv1.3 Ion Channel Screening Poster
- Nav1.5 LQT3 cardiac cell line Application Note
- ASIC1a QPatch assay Application Note
- Dynamic hERG assay QPatch Application Note
- ND7-23 neuroblastoma assay White Paper
Let’s work together
What are your specific ion channel and assay needs?
If you have any questions or would like to discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.